Limits...
Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease

View Article: PubMed Central - PubMed

ABSTRACT

This was the first multicenter, cross-sectional survey to assess the prevalence of anemia, patient awareness, and treatment status in China. Data of patients with chronic kidney disease (CKD; age, 18–75 years; both out- and inpatients) from 25 hospitals in Shanghai, seeking medical treatment at the nephrology department, were collected between July 1, 2012 and August 31, 2012. The prevalence, awareness, and treatment of anemia in patients with nondialysis CKD (ND-CKD) were assessed. Anemia was defined as serum hemoglobin (Hb) levels ≤12 g/dL in women and ≤13 g/dL in men. A total of 2420 patients with ND-CKD were included. Anemia was established in 1246 (51.5%) patients: 639 (51.3%) men and 607 (48.7%) women. The prevalence of anemia increased with advancing CKD stage (χ2trend = 675.14, P < 0.001). Anemia was more prevalent in patients with diabetic nephropathy (68.0%) than in patients with hypertensive renal damage (56.6%) or chronic glomerulonephritis (46.1%, both P < 0.001). Only 39.8% of the anemic patients received treatment with erythropoietin and 27.1% patients received iron products; furthermore, 22.7% of the patients started receiving treatment when their Hb level reached 7 g/dL. The target-achieving rate (Hb at 11–12 g/dL) was only 8.2%. Of the 1246 anemia patients, only 7.5% received more effective and recommended intravenous supplementation. Anemia is highly prevalent in patients with ND-CKD in China, with a low target-achieving rate and poor treatment patterns. The study highlights the need to improve multiple aspects of CKD management to delay the progression of renal failure.

No MeSH data available.


Related in: MedlinePlus

Prevalence rate of anemia.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4998459&req=5

Figure 1: Prevalence rate of anemia.

Mentions: The prevalence of anemia was 51.5% in the overall study sample, with 639 (51.3%) men and 607 (48.7%) women. An increasing trend of anemia was associated with advancing CKD stage (Fig. 1), that is, 22.4% in stage 1, 30.0% in stage 2, 51.1% in stage 3, 79.2% in stage 4, and 90.2% in stage 5 (χ2trend = 675.14, P < 0.001).


Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease
Prevalence rate of anemia.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4998459&req=5

Figure 1: Prevalence rate of anemia.
Mentions: The prevalence of anemia was 51.5% in the overall study sample, with 639 (51.3%) men and 607 (48.7%) women. An increasing trend of anemia was associated with advancing CKD stage (Fig. 1), that is, 22.4% in stage 1, 30.0% in stage 2, 51.1% in stage 3, 79.2% in stage 4, and 90.2% in stage 5 (χ2trend = 675.14, P < 0.001).

View Article: PubMed Central - PubMed

ABSTRACT

This was the first multicenter, cross-sectional survey to assess the prevalence of anemia, patient awareness, and treatment status in China. Data of patients with chronic kidney disease (CKD; age, 18&ndash;75 years; both out- and inpatients) from 25 hospitals in Shanghai, seeking medical treatment at the nephrology department, were collected between July 1, 2012 and August 31, 2012. The prevalence, awareness, and treatment of anemia in patients with nondialysis CKD (ND-CKD) were assessed. Anemia was defined as serum hemoglobin (Hb) levels &le;12&#8202;g/dL in women and &le;13&#8202;g/dL in men. A total of 2420 patients with ND-CKD were included. Anemia was established in 1246 (51.5%) patients: 639 (51.3%) men and 607 (48.7%) women. The prevalence of anemia increased with advancing CKD stage (&chi;2trend = 675.14, P&#8202;&lt;&#8202;0.001). Anemia was more prevalent in patients with diabetic nephropathy (68.0%) than in patients with hypertensive renal damage (56.6%) or chronic glomerulonephritis (46.1%, both P&#8202;&lt;&#8202;0.001). Only 39.8% of the anemic patients received treatment with erythropoietin and 27.1% patients received iron products; furthermore, 22.7% of the patients started receiving treatment when their Hb level reached 7&#8202;g/dL. The target-achieving rate (Hb at 11&ndash;12&#8202;g/dL) was only 8.2%. Of the 1246 anemia patients, only 7.5% received more effective and recommended intravenous supplementation. Anemia is highly prevalent in patients with ND-CKD in China, with a low target-achieving rate and poor treatment patterns. The study highlights the need to improve multiple aspects of CKD management to delay the progression of renal failure.

No MeSH data available.


Related in: MedlinePlus